Action 0IGA EMERGENT BIOSOLUTIONS INC
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Emergent Biosolutions Inc CINNOBER BOAT

Actions

0IGA

US29089Q1058

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
GL
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
GL
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day
GL
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024
GL
Emergent Biosolutions: Q1 Earnings Snapshot
AQ
Emergent BioSolutions Reports First Quarter 2024 Financial Results
GL
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
GL
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
GL
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
GL
Emergent BioSolutions to Release First Quarter 2024 Financial Results and Conduct Conference Call on May 1, 2024
AQ
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
GL
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
GL
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
GL
Emergent Biosolutions: Q4 Earnings Snapshot
AQ
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
GL
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
GL
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
GL
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
AQ
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
GL
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action EBS
  4. Action 0IGA
  5. Actualités Emergent Biosolutions Inc
  6. Communiqués